Clinical study on safety assessment of PRP therapy for iliopsoas impingement after total hip arthroplasty(PRP for illiopsoas impingement)

Clinical study on safety assessment of PRP therapy for iliopsoas impingement after total hip arthroplasty(PRP for illiopsoas impingement) - PRP for iliopsoas impingement

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTb030190272

Enrollment

Registered

2020-03-31

Start date

2019-07-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients who is diagnosed iliopsoas impingement after total hip arthroplasty

Interventions

administration of cell processing products.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients who have symptoms for more than 3 months 2.Patients who have continued pain even after taking NSAIDs for 6 week or more and who can not use NSAIDs for asthma and digestive tract ulcer 3. More than 20 years old 4. Other , patients who the doctor has determined that it is suitable for this clinicalstudy

Exclusion criteria

Exclusion criteria: 1. Patients with abnormal platelet counts in peripheral blood 2. Person who smokes a lot(Brinkmanindex>600) 3. Treatment with anticoagulants(Warfarin) 4. Uncontrolled diabetes mellitus :HbA1c not lower than 9.0% according to latest laboratory data obtained within 14 days before registration 5. Patients with malignancy 6. Patients less than 6 months after onset of cardiac infarction or cerebral infarction 7. Predictive survival period is less than 1 year 8.Active infectious disease (HBV, HCV, HTLV-1, HIV, syphilis) 9.Dialysis patients 10. Compromised host 11. Requiring continued use of oral corticosteroid therapy 12. Less than 20 years old 13. Doctor has determined that it is not suitable for this clinical study

Design outcomes

Primary

Measure	Time frame
safety	—

Secondary

Measure	Time frame
efficacy	—

Countries

Japan

Contacts

Public ContactYosuke Masubuchi

Juntendo university

y-masubuchi@juntendo.ac.jp+81-3-3814-5672

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026